Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes;Comparação de metformina, gliclazida MR e rosiglitazona em monoterapia e em combinação para o diabetes tipo 2

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 54, Issue 3, 2010, Pages 311-318

  Vilar, Lucio ^a,b   Canadas, Viviane ^b   Arruda, Maria Juliana ^b   Arahata, Carla ^b   Agra, Rodrigo ^b   Pontes, Lisete ^b   Montenegro, Larissa ^b   Vilar, Clarice Freitas ^a   e Silva, Lidiane Moura ^b   Albuquerque, José Luciano ^b   Gusmão, Amaro ^a,b  

^a Centro de Diabetes e Endocrinologia de Pernambuco   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Glicazide mr; Metformin; Rosiglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLICLAZIDE; METFORMIN; ROSIGLITAZONE;

ADULT; AGED; ANALYSIS OF VARIANCE; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; ANALYSIS OF VARIANCE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLICLAZIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 77953600879     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302010000300010     Document Type: Article

References (48)

1. Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-95.
2. Mizuno CS, Chittiboyina AG, Kurtz TW, Pershadsingh HA, Avery MA. Type 2 diabetes and oral antihyperglycemic drugs. Curr Med Chem. 2008;15(1):61-74.
3. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28(2):187-218.
4. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management - 2002 update. Endocr Pract. 2002;8 (suppl 1):40-82.
5. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA. 2002;287(3):360-72.
6. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65(3):385-411.
7. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8):1963-72.
8. Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin. 2007;23(4):945-52.
9. Cohen J, Colman P. Type 2 diabetes - the pharmacotherapy of glycaemic control and risk factor modification. Aust Fam Physician. 2006;35(6):380-4.
10. American Diabetes Association. Standards of medical care in Diabetes-2009. Diabetes Care. 2009;32(suppl 1):S13-S61.
11. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574-83.
12. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med.1995;333(9):541-9.
13. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352 (9131):854-65.
14. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89.
15. Lebowitz HE. Oral therapies for diabetic hyperglycemia therapy. Endocrinol Metab Clin North Am. 2001;30(4):909-33.
16. McGavin JK, Perry CM, Goa KL. Gliclazide modified release. Drugs. 2002;62(9):1357-64
17. discussion 1365-66
18. Drouin P, Standl E; Diamicron MR Study Group. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes. Diabetes Obes Metab. 2004;6(6):414-21.
19. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-72.
20. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism. 2006;55(5 Suppl 1):S20-7.
21. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P,Kvapil M, et al. GUIDE study: double-blind comparison of oncedaily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004;34(8):535-42.
22. Bailey CJ. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab. 2005;7(6):675-91.
23. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs. 2003;63(13):1373-405.
24. Wellington K. Rosiglitazone/ Metformin. Drugs. 2005;65(11):1581-92. discussion 1593-4.
25. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106-8.
26. Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther. 2005;27(10):1548-61.
27. Van Gaal LF, De Leeuw IH. Rational and options for combination therapy in the treatment of type 2 diabetes. Diabetologia. 2003;46 Suppl. 1: 44-50.
28. Bell DS. Type 2 diabetes mellitus: what is the optimal treatment regimen? Am J Med. 2004; 116(Suppl. 5A):23S-29S.
29. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
30. United Kingdom Prospective Diabetes Study (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.
31. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type 2 Diabetes. N Engl J Med. 2003;348(5):383-93.
32. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-43.
33. Green J, Feinglos M. New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vasc Health Risk Manag. 2008;4(4):743-51.
34. Raskin P, Lewin A, Reinhardt R, Lyness W; Repaglinide/Metformin Fixed-Dose Combination Study Group. Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet. Diabetes Obes Metab. 2009 May 19. [Epub ahead of print]
35. Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2006;8(6):650-60.
36. Kaku K. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial. Curr Med Res Opin. 2009;25(5):1111-9.
37. UKPDS 28. A randomized trial of efficacy of early addition of metformin in sulphonylurea-treated Type 2 diabetes. UK Prospective Diabetes Study (UKPDS) Group. Diabetes Care. 1998;21(1):87-92.
38. Chappuis B, Braun M, Stettler C, Allemann S, Diem P, Lumb PJ, et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev. 2007;23(5):392-9.
39. Granberry MC, Fonseca VA. Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. Am J Cardiovasc Drugs. 2005;5(3):201-9.
40. Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2006;8(2):156-63.
41. Derosa G, D'Angelo A, Ragonesi PD, Piccinni MN, Pricolo F, Salvadeo SA, et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther. 2006;31(4):375-83.
42. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-35.
43. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 dia betes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-89.
44. Kahn SE, Zinman B, Lachin JM, Herman WH, Holman RR, Kravitz BG, et al.; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31(5):845-51.
45. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-71. [Erratum, N Engl J Med. 2007;357 (1):100.]
46. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189-95.
47. Retnakaran R, Zinman B. Thiazolidinediones and clinical outcomes in type 2 diabetes. Lancet. 2009;373(9681):2088-90.
48. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180-8.